Adlai Nortye Ltd
ANL1.480USD
+0.030+2.07%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
163.84MCap. mercado
PérdidaP/E TTM
Más Datos de Adlai Nortye Ltd Compañía
Adlai Nortye Ltd is a Cayman Island-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of cancer therapies. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
Información de la empresa
Símbolo de cotizaciónANL
Nombre de la empresaAdlai Nortye Ltd
Fecha de salida a bolsaSep 29, 2023
Director ejecutivoMr. Lars Erik Birgerson
Número de empleados123
Tipo de seguridadDepository Receipt
Fin del año fiscalSep 29
Direcciónc/o PO Box 309
CiudadGRAND CAYMAN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCayman Islands
Código postalKY1-1104
Teléfono18482307430
Sitio Webhttps://www.adlainortye.com/
Símbolo de cotizaciónANL
Fecha de salida a bolsaSep 29, 2023
Director ejecutivoMr. Lars Erik Birgerson
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Mr. Ming Lun (Alan) Tse
Mr. Ming Lun (Alan) Tse
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Shaorong Liu
Mr. Shaorong Liu
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Kaiyang Tang
Dr. Kaiyang Tang
Senior Vice President, Global Head of Clinical Operations
Senior Vice President, Global Head of Clinical Operations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 24 de may
Actualizado: sáb., 24 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Nortye International Ltd
7.47%
Nortye Talent Ltd
1.12%
Cantor Fitzgerald, L.P
0.13%
Millennium Management LLC
0.04%
UBS Financial Services, Inc.
0.01%
Other
91.23%
Accionistas
Accionistas
Proporción
Nortye International Ltd
7.47%
Nortye Talent Ltd
1.12%
Cantor Fitzgerald, L.P
0.13%
Millennium Management LLC
0.04%
UBS Financial Services, Inc.
0.01%
Other
91.23%
Tipos de accionistas
Accionistas
Proporción
Corporation
14.25%
Investment Advisor
0.14%
Hedge Fund
0.04%
Other
85.57%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
8
4.51M
14.43%
+4.45M
2025Q1
8
4.51M
14.43%
+4.45M
2024Q4
5
2.23M
7.14%
+2.17M
2024Q3
5
2.24M
7.16%
+2.18M
2024Q2
5
2.23M
7.15%
+2.17M
2024Q1
5
2.23M
7.15%
+2.17M
2023Q4
5
2.24M
7.16%
+2.19M
2023Q3
3
48.25K
0.15%
+48.25K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Nortye International Ltd
2.33M
7.47%
+2.33M
--
Dec 31, 2024
Nortye Talent Ltd
349.27K
1.12%
+349.27K
--
Dec 31, 2024
Cantor Fitzgerald, L.P
40.31K
0.13%
--
--
Mar 31, 2025
Millennium Management LLC
11.56K
0.04%
-5.03K
-30.31%
Mar 31, 2025
UBS Financial Services, Inc.
4.67K
0.01%
+4.67K
+467400.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
19.00
0%
+19.00
--
Mar 31, 2025
Qube Research & Technologies Ltd
--
0%
-88.00
-100.00%
Sep 30, 2024
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
